世界の発達性＆てんかん性脳症（DEE）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Developmental and Epileptic Encephalopathies (DEE) Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4117 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、発達性＆てんかん性脳症（DEE）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（小児用非定型良性部分てんかん、ドラベト症候群、徐波睡眠時連続スパイク・アンド・ウェーブ発生型てんかん、視床下部てんかん、ランダウ・クレフナー症候群（LKS）、レノックス・ガストー症候群、非進行性脳症におけるミオクローヌス状態）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・発達性＆てんかん性脳症（DEE）の市場動向 ・企業の競争状況、市場シェア ・発達性＆てんかん性脳症（DEE）の種類別市場規模と予測2016-2027（小児用非定型良性部分てんかん、ドラベト症候群、徐波睡眠時連続スパイク・アンド・ウェーブ発生型てんかん、視床下部てんかん、ランダウ・クレフナー症候群（LKS）、レノックス・ガストー症候群、非進行性脳症におけるミオクローヌス状態） ・発達性＆てんかん性脳症（DEE）の用途別市場規模と予測2016-2027（病院、診療所、その他） ・発達性＆てんかん性脳症（DEE）の北米市場規模2016-2027（アメリカ、カナダ） ・発達性＆てんかん性脳症（DEE）の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・発達性＆てんかん性脳症（DEE）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・発達性＆てんかん性脳症（DEE）の中南米市場規模2016-2027（メキシコ、ブラジル） ・発達性＆てんかん性脳症（DEE）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Biocodex、Bio-Pharm Solutions、Eisai Pharmaceuticals、GlaxoSmithKline、Greenwich Biosciences、Janssen Pharmaceuticals、Lundbeck、Mylan Pharmaceuticals、PTC Therapeutics、Roche、Takeda Pharmaceutical、Zogenix、Zynerba Pharma、Ovid Therapeutics） ・結論

Developmental and Epileptic Encephalopathies (DEE) consists of several types of severe brain disorders in which the epileptic electrical discharges may add to progressive psychomotor dysfunction. They are a group of nosologies that are related to an early age and manifest with electroencephalography (EEG) paroxysmal activity that is often aggressive, seizures that are commonly multi-form and intractable, cognitive, behavioral and neurological deficits that may be relentless and sometimes lead to early death. Cognitive deficits and behavioral disturbances are presumed to be the main and sometimes the first and unique manifestation of electrographic epileptic discharges in epileptic encephalopathy. There are various sub syndromes in Epileptic encephalopathies namely West syndrome, Dravet syndrome, Ohtahara syndrome, Lennox-gastaut, Landau-Kleffner syndrome, Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep, Myoclonic Status in Non-Progressive Encephalopathies, Atypical Benign Partial Epilepsy of Childhood, Hypothalamic (Gelastic) Epilepsy.

Market Analysis and Insights: Global Developmental and Epileptic Encephalopathies (DEE) Market
The global Developmental and Epileptic Encephalopathies (DEE) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Developmental and Epileptic Encephalopathies (DEE) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Developmental and Epileptic Encephalopathies (DEE) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Developmental and Epileptic Encephalopathies (DEE) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Developmental and Epileptic Encephalopathies (DEE) market.

Global Developmental and Epileptic Encephalopathies (DEE) Scope and Market Size
Developmental and Epileptic Encephalopathies (DEE) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Developmental and Epileptic Encephalopathies (DEE) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Atypical Benign Partial Epilepsy of Childhood
Dravet Syndrome
Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep
Hypothalamic Epilepsy
Landau-Kleffner Syndrome (LKS)
Lennox-Gastaut Syndrome
Myoclonic Status in Non-Progressive Encephalopathies
West Syndrome

Segment by Application
Hospital
Clinic
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Biocodex
Bio-Pharm Solutions
Eisai Pharmaceuticals
GlaxoSmithKline
Greenwich Biosciences
Janssen Pharmaceuticals
Lundbeck
Mylan Pharmaceuticals
PTC Therapeutics
Roche
Takeda Pharmaceutical
Zogenix
Zynerba Pharma
Ovid Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Developmental and Epileptic Encephalopathies (DEE) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Atypical Benign Partial Epilepsy of Childhood
1.2.3 Dravet Syndrome
1.2.4 Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep
1.2.5 Hypothalamic Epilepsy
1.2.6 Landau-Kleffner Syndrome (LKS)
1.2.7 Lennox-Gastaut Syndrome
1.2.8 Myoclonic Status in Non-Progressive Encephalopathies
1.2.9 West Syndrome
1.3 Market by Application
1.3.1 Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Developmental and Epileptic Encephalopathies (DEE) Market Perspective (2016-2027)
2.2 Developmental and Epileptic Encephalopathies (DEE) Growth Trends by Regions
2.2.1 Developmental and Epileptic Encephalopathies (DEE) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Developmental and Epileptic Encephalopathies (DEE) Historic Market Share by Regions (2016-2021)
2.2.3 Developmental and Epileptic Encephalopathies (DEE) Forecasted Market Size by Regions (2022-2027)
2.3 Developmental and Epileptic Encephalopathies (DEE) Industry Dynamic
2.3.1 Developmental and Epileptic Encephalopathies (DEE) Market Trends
2.3.2 Developmental and Epileptic Encephalopathies (DEE) Market Drivers
2.3.3 Developmental and Epileptic Encephalopathies (DEE) Market Challenges
2.3.4 Developmental and Epileptic Encephalopathies (DEE) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Developmental and Epileptic Encephalopathies (DEE) Players by Revenue
3.1.1 Global Top Developmental and Epileptic Encephalopathies (DEE) Players by Revenue (2016-2021)
3.1.2 Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share by Players (2016-2021)
3.2 Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Developmental and Epileptic Encephalopathies (DEE) Revenue
3.4 Global Developmental and Epileptic Encephalopathies (DEE) Market Concentration Ratio
3.4.1 Global Developmental and Epileptic Encephalopathies (DEE) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Developmental and Epileptic Encephalopathies (DEE) Revenue in 2020
3.5 Developmental and Epileptic Encephalopathies (DEE) Key Players Head office and Area Served
3.6 Key Players Developmental and Epileptic Encephalopathies (DEE) Product Solution and Service
3.7 Date of Enter into Developmental and Epileptic Encephalopathies (DEE) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Developmental and Epileptic Encephalopathies (DEE) Breakdown Data by Type
4.1 Global Developmental and Epileptic Encephalopathies (DEE) Historic Market Size by Type (2016-2021)
4.2 Global Developmental and Epileptic Encephalopathies (DEE) Forecasted Market Size by Type (2022-2027)

5 Developmental and Epileptic Encephalopathies (DEE) Breakdown Data by Application
5.1 Global Developmental and Epileptic Encephalopathies (DEE) Historic Market Size by Application (2016-2021)
5.2 Global Developmental and Epileptic Encephalopathies (DEE) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Developmental and Epileptic Encephalopathies (DEE) Market Size (2016-2027)
6.2 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type
6.2.1 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021)
6.2.2 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027)
6.2.3 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2027)
6.3 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application
6.3.1 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021)
6.3.2 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027)
6.3.3 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2027)
6.4 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country
6.4.1 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2016-2021)
6.4.2 North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size (2016-2027)
7.2 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Type
7.2.1 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021)
7.2.2 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027)
7.2.3 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2027)
7.3 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Application
7.3.1 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021)
7.3.2 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027)
7.3.3 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2027)
7.4 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Country
7.4.1 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2016-2021)
7.4.2 Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size (2016-2027)
8.2 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Type
8.2.1 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2027)
8.3 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Application
8.3.1 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2027)
8.4 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Region
8.4.1 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size (2016-2027)
9.2 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type
9.2.1 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021)
9.2.2 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027)
9.2.3 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2027)
9.3 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application
9.3.1 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021)
9.3.2 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027)
9.3.3 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2027)
9.4 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country
9.4.1 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2016-2021)
9.4.2 Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size (2016-2027)
10.2 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Type
10.2.1 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2027)
10.3 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Application
10.3.1 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2027)
10.4 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Country
10.4.1 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Biocodex
11.1.1 Biocodex Company Details
11.1.2 Biocodex Business Overview
11.1.3 Biocodex Developmental and Epileptic Encephalopathies (DEE) Introduction
11.1.4 Biocodex Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.1.5 Biocodex Recent Development
11.2 Bio-Pharm Solutions
11.2.1 Bio-Pharm Solutions Company Details
11.2.2 Bio-Pharm Solutions Business Overview
11.2.3 Bio-Pharm Solutions Developmental and Epileptic Encephalopathies (DEE) Introduction
11.2.4 Bio-Pharm Solutions Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.2.5 Bio-Pharm Solutions Recent Development
11.3 Eisai Pharmaceuticals
11.3.1 Eisai Pharmaceuticals Company Details
11.3.2 Eisai Pharmaceuticals Business Overview
11.3.3 Eisai Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Introduction
11.3.4 Eisai Pharmaceuticals Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.3.5 Eisai Pharmaceuticals Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Developmental and Epileptic Encephalopathies (DEE) Introduction
11.4.4 GlaxoSmithKline Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.4.5 GlaxoSmithKline Recent Development
11.5 Greenwich Biosciences
11.5.1 Greenwich Biosciences Company Details
11.5.2 Greenwich Biosciences Business Overview
11.5.3 Greenwich Biosciences Developmental and Epileptic Encephalopathies (DEE) Introduction
11.5.4 Greenwich Biosciences Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.5.5 Greenwich Biosciences Recent Development
11.6 Janssen Pharmaceuticals
11.6.1 Janssen Pharmaceuticals Company Details
11.6.2 Janssen Pharmaceuticals Business Overview
11.6.3 Janssen Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Introduction
11.6.4 Janssen Pharmaceuticals Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.6.5 Janssen Pharmaceuticals Recent Development
11.7 Lundbeck
11.7.1 Lundbeck Company Details
11.7.2 Lundbeck Business Overview
11.7.3 Lundbeck Developmental and Epileptic Encephalopathies (DEE) Introduction
11.7.4 Lundbeck Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.7.5 Lundbeck Recent Development
11.8 Mylan Pharmaceuticals
11.8.1 Mylan Pharmaceuticals Company Details
11.8.2 Mylan Pharmaceuticals Business Overview
11.8.3 Mylan Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Introduction
11.8.4 Mylan Pharmaceuticals Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.8.5 Mylan Pharmaceuticals Recent Development
11.9 PTC Therapeutics
11.9.1 PTC Therapeutics Company Details
11.9.2 PTC Therapeutics Business Overview
11.9.3 PTC Therapeutics Developmental and Epileptic Encephalopathies (DEE) Introduction
11.9.4 PTC Therapeutics Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.9.5 PTC Therapeutics Recent Development
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Developmental and Epileptic Encephalopathies (DEE) Introduction
11.10.4 Roche Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.10.5 Roche Recent Development
11.11 Takeda Pharmaceutical
11.11.1 Takeda Pharmaceutical Company Details
11.11.2 Takeda Pharmaceutical Business Overview
11.11.3 Takeda Pharmaceutical Developmental and Epileptic Encephalopathies (DEE) Introduction
11.11.4 Takeda Pharmaceutical Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.11.5 Takeda Pharmaceutical Recent Development
11.12 Zogenix
11.12.1 Zogenix Company Details
11.12.2 Zogenix Business Overview
11.12.3 Zogenix Developmental and Epileptic Encephalopathies (DEE) Introduction
11.12.4 Zogenix Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.12.5 Zogenix Recent Development
11.13 Zynerba Pharma
11.13.1 Zynerba Pharma Company Details
11.13.2 Zynerba Pharma Business Overview
11.13.3 Zynerba Pharma Developmental and Epileptic Encephalopathies (DEE) Introduction
11.13.4 Zynerba Pharma Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.13.5 Zynerba Pharma Recent Development
11.14 Ovid Therapeutics
11.14.1 Ovid Therapeutics Company Details
11.14.2 Ovid Therapeutics Business Overview
11.14.3 Ovid Therapeutics Developmental and Epileptic Encephalopathies (DEE) Introduction
11.14.4 Ovid Therapeutics Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
11.14.5 Ovid Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Developmental and Epileptic Encephalopathies (DEE) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Atypical Benign Partial Epilepsy of Childhood
Table 3. Key Players of Dravet Syndrome
Table 4. Key Players of Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep
Table 5. Key Players of Hypothalamic Epilepsy
Table 6. Key Players of Landau-Kleffner Syndrome (LKS)
Table 7. Key Players of Lennox-Gastaut Syndrome
Table 8. Key Players of Myoclonic Status in Non-Progressive Encephalopathies
Table 9. Key Players of West Syndrome
Table 10. Global Developmental and Epileptic Encephalopathies (DEE) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Developmental and Epileptic Encephalopathies (DEE) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 12. Global Developmental and Epileptic Encephalopathies (DEE) Market Size by Regions (2016-2021) & (US$ Million)
Table 13. Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Regions (2016-2021)
Table 14. Global Developmental and Epileptic Encephalopathies (DEE) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 15. Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Regions (2022-2027)
Table 16. Developmental and Epileptic Encephalopathies (DEE) Market Trends
Table 17. Developmental and Epileptic Encephalopathies (DEE) Market Drivers
Table 18. Developmental and Epileptic Encephalopathies (DEE) Market Challenges
Table 19. Developmental and Epileptic Encephalopathies (DEE) Market Restraints
Table 20. Global Developmental and Epileptic Encephalopathies (DEE) Revenue by Players (2016-2021) & (US$ Million)
Table 21. Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Players (2016-2021)
Table 22. Global Top Developmental and Epileptic Encephalopathies (DEE) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Developmental and Epileptic Encephalopathies (DEE) as of 2020)
Table 23. Ranking of Global Top Developmental and Epileptic Encephalopathies (DEE) Companies by Revenue (US$ Million) in 2020
Table 24. Global 5 Largest Players Market Share by Developmental and Epileptic Encephalopathies (DEE) Revenue (CR5 and HHI) & (2016-2021)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Developmental and Epileptic Encephalopathies (DEE) Product Solution and Service
Table 27. Date of Enter into Developmental and Epileptic Encephalopathies (DEE) Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021) (US$ Million)
Table 30. Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share by Type (2016-2021)
Table 31. Global Developmental and Epileptic Encephalopathies (DEE) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 32. Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 33. Global Developmental and Epileptic Encephalopathies (DEE) Market Size Share by Application (2016-2021) & (US$ Million)
Table 34. Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share by Application (2016-2021)
Table 35. Global Developmental and Epileptic Encephalopathies (DEE) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 36. Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 37. North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021) (US$ Million)
Table 38. North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027) & (US$ Million)
Table 39. North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021) (US$ Million)
Table 40. North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027) & (US$ Million)
Table 41. North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2016-2021) & (US$ Million)
Table 42. North America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2022-2027) & (US$ Million)
Table 43. Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021) (US$ Million)
Table 44. Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027) & (US$ Million)
Table 45. Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021) (US$ Million)
Table 46. Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027) & (US$ Million)
Table 47. Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2016-2021) & (US$ Million)
Table 48. Europe Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021) (US$ Million)
Table 50. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021) (US$ Million)
Table 52. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027) & (US$ Million)
Table 53. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Region (2016-2021) & (US$ Million)
Table 54. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size by Region (2022-2027) & (US$ Million)
Table 55. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021) (US$ Million)
Table 56. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027) & (US$ Million)
Table 57. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021) (US$ Million)
Table 58. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027) & (US$ Million)
Table 59. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2016-2021) & (US$ Million)
Table 60. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2016-2021) (US$ Million)
Table 62. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Type (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2016-2021) (US$ Million)
Table 64. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Application (2022-2027) & (US$ Million)
Table 65. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2016-2021) & (US$ Million)
Table 66. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size by Country (2022-2027) & (US$ Million)
Table 67. Biocodex Company Details
Table 68. Biocodex Business Overview
Table 69. Biocodex Developmental and Epileptic Encephalopathies (DEE) Product
Table 70. Biocodex Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 71. Biocodex Recent Development
Table 72. Bio-Pharm Solutions Company Details
Table 73. Bio-Pharm Solutions Business Overview
Table 74. Bio-Pharm Solutions Developmental and Epileptic Encephalopathies (DEE) Product
Table 75. Bio-Pharm Solutions Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 76. Bio-Pharm Solutions Recent Development
Table 77. Eisai Pharmaceuticals Company Details
Table 78. Eisai Pharmaceuticals Business Overview
Table 79. Eisai Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Product
Table 80. Eisai Pharmaceuticals Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 81. Eisai Pharmaceuticals Recent Development
Table 82. GlaxoSmithKline Company Details
Table 83. GlaxoSmithKline Business Overview
Table 84. GlaxoSmithKline Developmental and Epileptic Encephalopathies (DEE) Product
Table 85. GlaxoSmithKline Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 86. GlaxoSmithKline Recent Development
Table 87. Greenwich Biosciences Company Details
Table 88. Greenwich Biosciences Business Overview
Table 89. Greenwich Biosciences Developmental and Epileptic Encephalopathies (DEE) Product
Table 90. Greenwich Biosciences Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 91. Greenwich Biosciences Recent Development
Table 92. Janssen Pharmaceuticals Company Details
Table 93. Janssen Pharmaceuticals Business Overview
Table 94. Janssen Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Product
Table 95. Janssen Pharmaceuticals Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 96. Janssen Pharmaceuticals Recent Development
Table 97. Lundbeck Company Details
Table 98. Lundbeck Business Overview
Table 99. Lundbeck Developmental and Epileptic Encephalopathies (DEE) Product
Table 100. Lundbeck Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 101. Lundbeck Recent Development
Table 102. Mylan Pharmaceuticals Company Details
Table 103. Mylan Pharmaceuticals Business Overview
Table 104. Mylan Pharmaceuticals Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 105. Mylan Pharmaceuticals Recent Development
Table 106. PTC Therapeutics Company Details
Table 107. PTC Therapeutics Business Overview
Table 108. PTC Therapeutics Developmental and Epileptic Encephalopathies (DEE) Product
Table 109. PTC Therapeutics Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 110. PTC Therapeutics Recent Development
Table 111. Roche Company Details
Table 112. Roche Business Overview
Table 113. Roche Developmental and Epileptic Encephalopathies (DEE) Product
Table 114. Roche Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 115. Roche Recent Development
Table 116. Takeda Pharmaceutical Company Details
Table 117. Takeda Pharmaceutical Business Overview
Table 118. Takeda Pharmaceutical Developmental and Epileptic Encephalopathies (DEE) Product
Table 119. Takeda Pharmaceutical Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 120. Takeda Pharmaceutical Recent Development
Table 121. Zogenix Company Details
Table 122. Zogenix Business Overview
Table 123. Zogenix Developmental and Epileptic Encephalopathies (DEE) Product
Table 124. Zogenix Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 125. Zogenix Recent Development
Table 126. Zynerba Pharma Company Details
Table 127. Zynerba Pharma Business Overview
Table 128. Zynerba Pharma Developmental and Epileptic Encephalopathies (DEE) Product
Table 129. Zynerba Pharma Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 130. Zynerba Pharma Recent Development
Table 131. Ovid Therapeutics Company Details
Table 132. Ovid Therapeutics Business Overview
Table 133. Ovid Therapeutics Developmental and Epileptic Encephalopathies (DEE) Product
Table 134. Ovid Therapeutics Revenue in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021) & (US$ Million)
Table 135. Ovid Therapeutics Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Type: 2020 VS 2027
Figure 2. Atypical Benign Partial Epilepsy of Childhood Features
Figure 3. Dravet Syndrome Features
Figure 4. Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep Features
Figure 5. Hypothalamic Epilepsy Features
Figure 6. Landau-Kleffner Syndrome (LKS) Features
Figure 7. Lennox-Gastaut Syndrome Features
Figure 8. Myoclonic Status in Non-Progressive Encephalopathies Features
Figure 9. West Syndrome Features
Figure 10. Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Application: 2020 VS 2027
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Others Case Studies
Figure 14. Developmental and Epileptic Encephalopathies (DEE) Report Years Considered
Figure 15. Global Developmental and Epileptic Encephalopathies (DEE) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Developmental and Epileptic Encephalopathies (DEE) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Regions: 2020 VS 2027
Figure 18. Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Regions (2022-2027)
Figure 19. Global Developmental and Epileptic Encephalopathies (DEE) Market Share by Players in 2020
Figure 20. Global Top Developmental and Epileptic Encephalopathies (DEE) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Developmental and Epileptic Encephalopathies (DEE) as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Developmental and Epileptic Encephalopathies (DEE) Revenue in 2020
Figure 22. Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share by Type (2016-2021)
Figure 23. Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share by Type (2022-2027)
Figure 24. North America Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Developmental and Epileptic Encephalopathies (DEE) Market Share by Type (2016-2027)
Figure 26. North America Developmental and Epileptic Encephalopathies (DEE) Market Share by Application (2016-2027)
Figure 27. North America Developmental and Epileptic Encephalopathies (DEE) Market Share by Country (2016-2027)
Figure 28. United States Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Developmental and Epileptic Encephalopathies (DEE) Market Share by Type (2016-2027)
Figure 32. Europe Developmental and Epileptic Encephalopathies (DEE) Market Share by Application (2016-2027)
Figure 33. Europe Developmental and Epileptic Encephalopathies (DEE) Market Share by Country (2016-2027)
Figure 34. Germany Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Developmental and Epileptic Encephalopathies (DEE) Market Share by Region (2016-2027)
Figure 44. China Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Share by Type (2016-2027)
Figure 52. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Share by Application (2016-2027)
Figure 53. Latin America Developmental and Epileptic Encephalopathies (DEE) Market Share by Country (2016-2027)
Figure 54. Mexico Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Market Share by Country (2016-2027)
Figure 60. Turkey Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Developmental and Epileptic Encephalopathies (DEE) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Biocodex Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 64. Bio-Pharm Solutions Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 65. Eisai Pharmaceuticals Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 66. GlaxoSmithKline Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 67. Greenwich Biosciences Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 68. Janssen Pharmaceuticals Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 69. Lundbeck Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 70. Mylan Pharmaceuticals Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 71. PTC Therapeutics Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 72. Roche Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 73. Takeda Pharmaceutical Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 74. Zogenix Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 75. Zynerba Pharma Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 76. Ovid Therapeutics Revenue Growth Rate in Developmental and Epileptic Encephalopathies (DEE) Business (2016-2021)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

---